Clinical Scorecard: FDA Advances Menopause Care Through Updated Hormone Therapy Labels and Efforts to Expand Supply

At a Glance

Key Highlights

• FDA approved revised labeling for three additional estradiol transdermal patch products.
• The revised boxed warnings no longer include outdated statements about cardiovascular disease, breast cancer, or probable dementia.
• FDA reported no imminent risk of a nationwide shortage based on current information, while acknowledging localized difficulty obtaining some products.
• Manufacturers have doubled total market output of estradiol patches over the past 12 months through measures including increased capacity and additional shifts.
• FDA is assessing supply options, including specified compounding flexibilities, and working with sponsors on whether vaginal estrogen products could be available over the counter.

Guideline-Based Recommendations

Diagnosis

Management

• Women unable to find their customary patch are encouraged to consult a pharmacist or healthcare provider about an available alternative or equivalent suited to their individual needs.
• FDA-approved nonprescription vaginal estrogen would require agency approval based on evidence that consumers can select and use the products safely and effectively without healthcare professional supervision.
• 503A pharmacy compounding remains available for individualized patient needs under certain conditions, including a valid prescription for an identified individual patient.

Monitoring & Follow-up

• FDA is monitoring the supply of approved MHT products, including patches, gels, and creams, and is communicating with manufacturers.
• FDA is continuing discussions with the six manufacturers of FDA-approved estradiol patches regarding access amid increased demand.

Risks

• FDA reported no imminent risk of a nationwide shortage based on current information, but has received reports of localized difficulty obtaining usual MHT products.
• Availability may vary by brand, strength, once-weekly or twice-weekly formulation, and geographic location.
• Under FDA's interim policy, the agency does not intend to pursue action against qualifying 503B outsourcing facilities compounding drugs containing designated Category 1 bulk drug substances, subject to specified conditions.

Patient & Prescribing Data

Women considering or receiving menopausal hormone therapy; the article provides no patient-level demographic or prescribing data.

The article reports labeling and supply actions, not comparative treatment outcomes or dosing guidance. Patients who cannot obtain their usual patch are encouraged to discuss available alternatives with a pharmacist or healthcare provider.

Clinical Best Practices

• Consult a pharmacist or healthcare provider if the usual estradiol patch is unavailable, since product availability varies by brand, strength, formulation, and location.
• Use 503A compounded products for individualized needs only under applicable conditions, including a valid prescription for an identified patient.
• FDA's stated 503B enforcement discretion applies only when the specified policy conditions are satisfied.

Related Resources & Content

• FDA Authorizes Labeling Revisions for Menopausal Hormone Therapy Products
• To clarify safety information and benefit–risk considerations, FDA requests labeling changes for menopausal hormone therapies
• FDA Update: Availability of Transdermal Estradiol Patches
• Updated Prescribing Information for Menopausal Hormone Therapy